These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12455205)

  • 21. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
    Weiss M; Wasdell M; Patin J
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1415-21. PubMed ID: 15502601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
    Silva R; Tilker HA; Cecil JT; Kowalik S; Khetani V; Faleck H; Patin J
    J Child Adolesc Psychopharmacol; 2004; 14(4):555-63. PubMed ID: 15662147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats.
    Teo SK; Stirling DI; Thomas SD; Khetani VD
    Pharmacol Biochem Behav; 2003 Feb; 74(3):747-54. PubMed ID: 12543241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.
    Markowitz JS; DeVane CL; Pestreich LK; Patrick KS; Muniz R
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):687-98. PubMed ID: 17201613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Jornay PM -- evening-dosed methylphenidate for ADHD.
    Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
    [No Abstract]   [Full Text] [Related]  

  • 28. Extended-release methylphenidate (Ritalin LA).
    Lyseng-Williamson KA; Keating GM
    Drugs; 2002; 62(15):2251-9; discussion 2260-1. PubMed ID: 12381228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
    Markowitz JS; Straughn AB; Patrick KS
    Pharmacotherapy; 2003 Oct; 23(10):1281-99. PubMed ID: 14594346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.
    Childress AC; Cutler AJ; Patel M; Oh C
    J Child Adolesc Psychopharmacol; 2023 May; 33(4):134-142. PubMed ID: 37204277
    [No Abstract]   [Full Text] [Related]  

  • 33. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
    Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
    J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
    Silva RR; Brams M; McCague K; Pestreich L; Muniz R
    Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.
    Braeckman R; Guenther S; Mickle TC; Barrett AC; Smith A; Oh C
    J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):288-295. PubMed ID: 35666231
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.
    Lopez F; Silva R; Pestreich L; Muniz R
    Paediatr Drugs; 2003; 5(8):545-55. PubMed ID: 12895137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.
    Patrick KS; Straughn AB
    Drug Metab Dispos; 2016 Mar; 44(3):418-21. PubMed ID: 26729760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.